Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

Paths of FGFR-driven tumorigenesis

(2010) Victor D. Acevedo et al.   CELL CYCLE

Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2-Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors

(2010) A. C. Mita et al.   CLINICAL CANCER RESEARCH

PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment

(2009) Yongping Crawford et al.   CANCER CELL

Mediators of Glioblastoma Resistance and Invasion during Antivascular Endothelial Growth Factor Therapy

(2009) A. K. Lucio-Eterovic et al.   CLINICAL CANCER RESEARCH

7105 Phase II trial of the oral multikinase inhibitor BAY 73–4506 as 1st-line therapy in patients with metastatic or unresectable renal cell cancer (RCC)

(2009) T. Eisen et al.   EJC SUPPLEMENTS

Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors

(2009) Roy S. Herbst et al.   JOURNAL OF CLINICAL ONCOLOGY

Tie2 in Tumor Endothelial Signaling and Survival: Implications for Antiangiogenic Therapy

(2009) J. H. Tsai et al.   MOLECULAR CANCER RESEARCH

Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system

(2009) Hellmut G. Augustin et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Targeting RET for thyroid cancer therapy

(2008) Cinzia Lanzi et al.   BIOCHEMICAL PHARMACOLOGY

Angiogenic Switch of Angiopietins-Tie2 System and Its Prognostic Value in Bladder Cancer

(2008) T. Szarvas et al.   CLINICAL CANCER RESEARCH